Celltrion Launches 'Aptozma' in Three European Countries... Secures 80% of French Private Market Tender
Increase in Yuflyma Prescriptions in Germany
Selected as Supplier by Ministry of Health Bidding Agency in Spain
Celltrion announced on January 30 that it has launched Aptozma (ingredient: tocilizumab), a treatment for autoimmune diseases, in major European countries including Germany, France, and Spain.
In France, the company secured the majority of supply volume through a private hospital group tender, accounting for approximately 80% of the private tocilizumab market in the country. Celltrion explained that it gained a competitive edge in the bidding process by emphasizing supply stability. In the retail market, the company is working to expand prescriptions by leveraging its established network of healthcare professionals, built through the sales of existing autoimmune disease treatments such as Remsima SC (ingredient: infliximab) and Yuflyma (ingredient: adalimumab).
Celltrion's French subsidiary also plans to conduct observational clinical studies to collect real-world prescription data. These studies, currently underway for Stekima (ingredient: ustekinumab) and Omriclo (ingredient: omalizumab), aim to evaluate the effects of switching to Aptozma and patient satisfaction. The company also intends to add Aidentzelt (ingredient: aflibercept) to these studies.
In Germany, Celltrion is focusing on expanding Aptozma sales through its local sales team. The company highlights the additional real-world safety data being collected for the intravenous formulation of Aptozma as a differentiating factor. Since the launch of Aptozma, prescriptions for Yuflyma, another autoimmune disease treatment, have also increased, resulting in a portfolio expansion effect.
In Spain, Celltrion has continued to win regional public tenders. The Spanish subsidiary secured supply contracts for Aptozma in key regions such as the Basque Country, Madrid, and Andalusia. It was also selected as a supplier in a tender organized by INGESA, a bidding agency under the Ministry of Health. In Spain, Celltrion launched a 400mg formulation that is not available in the original product.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A Celltrion representative stated, "With Aptozma, our fifth autoimmune disease treatment, successfully launched in major European countries, we plan to rapidly secure a leading position in the global tocilizumab market by leveraging the sales experience we have accumulated from our existing products," adding, "We will continue to strengthen our market dominance."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.